Last reviewed · How we verify
NCT04872374
Effects of Parmigiano Reggiano on Skeletal Muscle Damage in Older Adults
NA trial testing Parmigiano Reggiano in Old Age; Atrophy in 20 participants. Status unknown.
31 October 2021
Quick facts
| Lead sponsor | University of Padova |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 1 May 2021 |
| Primary completion | 31 October 2021 |
| Estimated completion | 1 March 2022 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Parmigiano Reggiano
- Whey Protein
Conditions studied
- Old Age; Atrophy — all drugs for Old Age; Atrophy →
- Inflammatory Response — all drugs for Inflammatory Response →
- Muscle Soreness — all drugs for Muscle Soreness →
Sponsor
University of Padova
Who can join
18 and older, any sex, with Old Age; Atrophy or Inflammatory Response. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Aging is associated with the loss of muscle mass and function (sarcopenia) and reduced tissue regenerative capacity. Eccentric exercise (ECC) is a model of RET that can be used with the elderly, due to the ability of the muscle to combine high muscle strength production with low energy cost. ECC contractions are significantly more damaging to the muscles and produce greater muscle strength, for these reasons there is a greater risk of inducing muscle damage before the muscle is able to adapt. Parmigiano Reggiano (PR) has some peculiar bromatological characteristics. The proteins contained in it, and in particular the potentially bioactive peptide sequences, can rapidly provide the amino acids necessary to promote muscle growth and repair during exercise. Furthermore, PR can be an important source of fatty acids, of which a significant amount of short-chain fatty acids (SCFA) which are known to have important clinical effects on body composition and metabolic health and can have a systemic anti-inflammatory effect. Therefore, the central hypothes is that PR consumed during RET can provide more energy substrates and improve muscle recovery. To date, no studies have studied its function on recovery from exercise nor in the elderly.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04872374
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Parmigiano Reggiano
Trials testing the same drug.
- NCT04861857 — Effects of Parmigiano Reggiano on Muscle and Inflammatory Response to Eccentric Resistance Training in Older Adults · NA · unknown
Other recruiting trials for Old Age; Atrophy
Currently open trials in the same condition.
- NCT06363942 — A Personalized Video-based Exercise Program for Fall Prevention in Frail and Pre-frail Older Adult · NA · recruiting
- NCT05413616 — The Effect of a Combined Personalized Nutritional Intervention and a Personalized Graded Activity Functional Training Pr · NA · recruiting
Other University of Padova trials
Trials by the same sponsor.
- NCT07435064 — NURsing-led FRAILty Prevention and Care · NA · not yet recruiting
- NCT07283354 — Comparison of Acceleromyography and Electromyography in Obese Patients Undergoing General Anesthesia · not yet recruiting
- NCT07259460 — Effects of Dexmedetomidine Target Controlled Infusion on Patient State Index Values and Electroencephalographic Spectrum · recruiting
- NCT07385118 — Daily Fluctuations in Brain-Derived Neurotrophic Factor and Cognition: Effects of Vigorous Exercise · NA · completed
- NCT07259291 — Minto and Eleveld Remifentanil Target Controlled Infusion (TCI) Models: a Clinical Comparison · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04872374 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Padova
- Last refreshed: 4 May 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04872374.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing